Duchenne Now

Duchennne UK is delighted to announce that Duchenne Now is joining forces with us to help accelerate our fight for treatments and a cure for Duchenne muscular dystrophy.

Duchenne UK, the parent led charity dedicated to accelerating the search for treatments and a cure for Duchenne Muscular Dystrophy (DMD), is pleased to announce that Duchenne Now is joining Duchenne UK.

Duchenne Now was founded in 2012, by parents of children and young adults with Duchenne, who between them, have more than 20 years of dedicated Duchenne charity experience.

Their charity was born out of their desire to ensure transparency, accountability and an ambition that all funded projects had a clear road map to market. Duchenne Now and Duchenne UK share the same dedication in our joint mission to fund and accelerate the search for treatments and a cure for Duchenne for all.

Tony Levene, founder and trustee of Duchenne Now said:

“We’ve been working alongside Alex and Emily from Duchenne UK for many years, and I am blown away by the progress they have made. They have attended hundreds of meetings, and have put many quality projects together that Duchenne Now and others have supported. I feel that it is in the best interests of the community for us to join forces, because together we will be stronger.

Vici Richardson founder and trustee of Duchenne Now said:

“Over the last five years I am proud to say that, with the support of our members, we have contributed over half a million pounds across many projects with more still in pipeline. Plus, we have ensured a shift in how charities in our community are working. Joining forces with Duchenne UK is the next logical step – to share our knowledge, our advocacy experience, our funds and expertise to accelerate the fight for a cure.”

Emily Crossley & Alex Johnson from Duchene UK said:

“We are delighted that Duchenne Now is joining forces with us, and we want to thank their members for supporting this move. We deeply value the advice, expertise and view of their founders and trustees to bring their long history of working in the DMD space.”

Duchenne UK was formed in 2016 through the coming together of the Duchenne Children’s Trust and Joining Jack. Since then, the charity is proud to have been joined by Alex’s Wish as a charity partner, who works with Duchenne UK to fund vital research into treatments for this generation.

The charity is also hugely grateful to all its supporters, including the many parents and families who support us either directly, through their own charities or through our Friends and Family Funds.

Latest

Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

We are excited to share the news with the Duchenne community highlighting an important advancement in the Phase 1b, Multicenter, Open-label, Single Ascending Dose Study.
Soy Products Study: Your Questions Answered

Duchenne UK recently posted a publication by Professor Steve Winder investigating a nutraceutical soy project Haelan 951. Following the publication, Duchenne UK have collated some of the questions from the Duchenne community and working with Steve Winder we have answered them.
VISION-DMD Update:

VISION-DMD is an EC funded project undertaking Phase 2 clinical studies on vamorolone, a new treatment for DMD. Vamorolone (also known as VBP15) is a dissociative steroid designed to have the efficacy of a steroid, without the severe associated side effects. The first Phase 2b study site is expected to open for recruitment in April 2018
An update on soy product research funded by Duchenne UK

In August 2016 Duchenne UK commissioned Professor Steve Winder at The University of Sheffield to investigate a nutraceutical soy product called Haelan 951, as a treatment for Duchenne muscular dystrophy. Results of the study published today in PLOS Currents.